Novo Nordisk is investing 2.1 billion Danish kroner ($306 million) in a new 10,300-square-meter facility in Hillerød, Denmark. The facility will produce medicines for the treatment of diabetes and obesity. The company held a groundbreaking ceremony marking the start of construction.

The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people.

Established in 1992, the Hillerød site covers an area of about 1,650,000 square meters, of which 90,000 square meters is used for production, research, and development. The site houses a facility for device R&D and three production facilities: one for molding and pre-assembly of components; one for filling, assembly, and packaging of diabetes finished products; and one for the production of active pharmaceutical ingredients for hemophilia products. Novo Nordisk has made ongoing investments in the site of approximately 350 million kroner ($51 million) per year on average.

Source: Novo Nordisk